| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Cui X | |
| Lee AV | |||
| Oesterreich S | |||
| P433 | issue | 12 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | preproinsulin | Q7240673 |
| estrogen | Q277954 | ||
| P304 | page(s) | 4429s-4435s; discussion 4411s-4412s | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer | |
| P478 | volume | 7 |
| Q37105231 | A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors |
| Q37255088 | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications |
| Q34077845 | Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells |
| Q36860992 | Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance |
| Q28533543 | Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response |
| Q39558942 | Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. |
| Q24813627 | Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer |
| Q30471838 | Estrogen receptor expression in sporadic vestibular schwannomas |
| Q35783042 | Estrogen receptor pathways in lung cancer |
| Q56962789 | Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma |
| Q28084982 | From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? |
| Q35786706 | Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. |
| Q36734550 | Gαo potentiates estrogen receptor α activity via the ERK signaling pathway |
| Q37038068 | HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. |
| Q92382325 | Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer |
| Q35093102 | Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions: a study on postmenopausal monozygotic twin pairs |
| Q35726382 | Identification of therapeutic targets for breast cancer using biological informatics methods |
| Q30419413 | Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer |
| Q37280601 | Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens |
| Q42160729 | Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung |
| Q35051765 | Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q36851417 | Mechanisms of Endocrine Resistance in Breast Cancer |
| Q35469769 | NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. |
| Q55342026 | Overcoming endocrine resistance in hormone receptor-positive breast cancer. |
| Q35809136 | Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial |
| Q33642075 | Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells. |
| Q38884380 | Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro. |
| Q38841650 | Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro. |
| Q36955067 | The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer |
| Q36336601 | The changing role of ER in endocrine resistance |
| Q94527304 | The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies |
| Q44686547 | Tissue-specific regulation by estrogen of ezrin and ezrin/radixin/moesin-binding protein 50. |
Search more.